Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Teva Pharmaceutical Industries Ltd

Teva to Present at the Jefferies London Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Statement on European Commission Decision; Company to Appeal
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Present at the Bank of America 2024 Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.